In honor of Ochsner Hospital in New Orleans being recognized as the number one hospital in the nation for liver transplants and the fact that I’m studying Hepatitis C in France, I decided to make a post on the virus that got me interested in virology in the first place. Most recently, Hepatitis C viral treatments have been in the news several times over the past year, mainly focusing around a new drug called Sofosbuvir that has shown a nearly 100% cure rate for those with certain genotypes of HCV. But did you know there are four other types of hepatitis viruses, each functioning in their own special way? With over 500 million people worldwide suffering from a Hepatitis virus, it has become a major public health problem.
There are five different types of viral hepatitis. While initial thinking may lead you to believe that they are all closely related, the truth is far from that.
___________________________________________________________________________________
Before I dive into the ABC’s of viral hepatitis, I also want to give a few definitions that are frequently used throughout this post.
Kb: Kilobases; the number of base pairs (AT, GC) that the virus has x 1000.
Polyprotein: A large amino acid sequence consisting of many different protein sequences. Once the viral genome is translated by the host cell’s machinery, post-translation modifications cleave the translated polyprotein into different structural and non-structural proteins.
Non-Structural Proteins: Proteins found in the viral genome that are used to help with replication and other viral processes inside the cell, but do not contribute to the shape of the virus.
Structural Proteins: Proteins they surround the viral genome and give the virus its shape. They also can help viruses enter host cells by interacting with surface proteins on the host cell. Think of structural proteins as the “scaffolding” of the virus.
Chronic vs Acute Infection: To summarize, an acute infection is the infection that initially develops after exposure to the virus. A chronic infection is an ongoing infection that lasts six months or longer.
____________________________________________________________________________________
Hepatitis A Virus
HAV is a non-envelopped, positive sense RNA virus ~7.5kb long. It is a member of the Picornaviridae family. Like other picornaviruses, it is spread through the fecal-oral route. After about 28 days of incubation, those who exhibit symptoms often show signs of jaundice, fever, general malaise, and dark urine, among others. HAV has not been shown to develop into a chronic infection. A vaccine is available against HAV and is often included in normal vaccination schedules.
Hepatits B Virus
HBV is a partially double-stranded DNA virus about 3.2 kb long. Unlike HAV and other RNA viruses, HBV uses a different mechanism to convert make an RNA copy of its genome which the infected host cell then translates. As a member of the Hepadnavirus family, it has high levels of genetic variability. HBV is spread through mucosal contact with bodily fluids or through cuts in the skin exposed to infected bodily fluids. About 25% of all infections will become chronic; HBV is also one of the leading causes of Hepatocellular Carcinoma (HCC) , a form of liver cancer. There are 8 human genotypes of HBV, and three other possible genotypes found in apes. The HBV vaccines protects against all known genotypes.
Hepatitis C Virus
HCV is an enveloped, positive sense RNA virus about 9.6 kb long. Its family Flaviviridae and genus Hepacivirus includes viruses like west nile virus and yellow fever. The seven different genotypes of HCV, the difficulty of studying HCV in vitro and in vivo, and high mutation rate of the virus has made it impossible thus far to develop a vaccine, though developments are underway. While it is an RNA virus like HAV, in most individuals (75-80%) it develops into a chronic infection and can cause HCC like HBV. The current treatment for HCV includes a cocktail of anti-viral drugs designed to inhibit further HCV synthesis. As HCV is spread through contact with infected blood, intravenous drug users are at a high risk for HCV.
Hepatits D Virus
HDV is a negative sense RNA virus about 1.7 kb long. It relies on the HBV viral envelope to form complex in order to assemble and infect. Only about 5% of HBV patients have a HDV co-infection, yet those with HDV are more likely to develop serious liver disease. While no vaccine is available against HDV, HBV vaccination prevents HDV.
Hepatitis E Virus
HEV is a non-enveloped, positive sense RNA virus about 7.2 kb long. Is is spread through the fecal-oral route and causes acute hepatitis. There are four different genotypes of HEV in the Hepeviridae family. While HEV is not much of an issue in the US, it is endemic in many countries around the world. In particular, mortality rates of up to 30% have been cited in pregnant women who contact HEV. No vaccine is currently available, and treatment focuses on relief of symptoms over treating the infection.
___________________________________________________________________________________
The easiest and most effective ways to avoid viral hepatitis transmission is to follow standard hygiene practices. As with other sexually transmitted diseases, safe sex practices reduce the risk of transmission. Regular STD testing is important, as viral hepatitis can be asymptomatic. Those in healthcare and other high-risk settings are vaccinated against Hepatitis B; the vaccine is available to others who desire it.
The viral hepatitis viruses are not the only viruses that can cause liver inflammation and disease. Cytomegalovirus, Epstein-Barr Virus, Herpes Simplex Virus, and Yellow Fever have all been shown to cause liver inflammation.
Sources:
http://www.cdc.gov/hepatitis/
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1360271/
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3294142/
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2517704/
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897199/
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782269/
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823334/
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630916/